Targeted drug tested for Tough-to-Treat female cancers
NCT ID NCT06865677
Summary
This study aimed to test if a drug called sacituzumab govitecan could help control recurrent ovarian, endometrial, or cervical cancers that had returned after at least two prior treatments. The drug was given by IV infusion to see if it could shrink tumors. The trial was terminated early after enrolling only 2 participants, so no results are available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLATINUM RESISTANT EPITHELIAL OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.